- •Table of Contents
- •Copyright
- •Dedication
- •Introduction to the eighth edition
- •Online contents
- •List of Illustrations
- •List of Tables
- •1. Pulmonary anatomy and physiology: The basics
- •Anatomy
- •Physiology
- •Abnormalities in gas exchange
- •Suggested readings
- •2. Presentation of the patient with pulmonary disease
- •Dyspnea
- •Cough
- •Hemoptysis
- •Chest pain
- •Suggested readings
- •3. Evaluation of the patient with pulmonary disease
- •Evaluation on a macroscopic level
- •Evaluation on a microscopic level
- •Assessment on a functional level
- •Suggested readings
- •4. Anatomic and physiologic aspects of airways
- •Structure
- •Function
- •Suggested readings
- •5. Asthma
- •Etiology and pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features
- •Diagnostic approach
- •Treatment
- •Suggested readings
- •6. Chronic obstructive pulmonary disease
- •Etiology and pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features
- •Diagnostic approach and assessment
- •Treatment
- •Suggested readings
- •7. Miscellaneous airway diseases
- •Bronchiectasis
- •Cystic fibrosis
- •Upper airway disease
- •Suggested readings
- •8. Anatomic and physiologic aspects of the pulmonary parenchyma
- •Anatomy
- •Physiology
- •Suggested readings
- •9. Overview of diffuse parenchymal lung diseases
- •Pathology
- •Pathogenesis
- •Pathophysiology
- •Clinical features
- •Diagnostic approach
- •Suggested readings
- •10. Diffuse parenchymal lung diseases associated with known etiologic agents
- •Diseases caused by inhaled inorganic dusts
- •Hypersensitivity pneumonitis
- •Drug-induced parenchymal lung disease
- •Radiation-induced lung disease
- •Suggested readings
- •11. Diffuse parenchymal lung diseases of unknown etiology
- •Idiopathic pulmonary fibrosis
- •Other idiopathic interstitial pneumonias
- •Pulmonary parenchymal involvement complicating systemic rheumatic disease
- •Sarcoidosis
- •Miscellaneous disorders involving the pulmonary parenchyma
- •Suggested readings
- •12. Anatomic and physiologic aspects of the pulmonary vasculature
- •Anatomy
- •Physiology
- •Suggested readings
- •13. Pulmonary embolism
- •Etiology and pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features
- •Diagnostic evaluation
- •Treatment
- •Suggested readings
- •14. Pulmonary hypertension
- •Pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features
- •Diagnostic features
- •Specific disorders associated with pulmonary hypertension
- •Suggested readings
- •15. Pleural disease
- •Anatomy
- •Physiology
- •Pleural effusion
- •Pneumothorax
- •Malignant mesothelioma
- •Suggested readings
- •16. Mediastinal disease
- •Anatomic features
- •Mediastinal masses
- •Pneumomediastinum
- •Suggested readings
- •17. Anatomic and physiologic aspects of neural, muscular, and chest wall interactions with the lungs
- •Respiratory control
- •Respiratory muscles
- •Suggested readings
- •18. Disorders of ventilatory control
- •Primary neurologic disease
- •Cheyne-stokes breathing
- •Control abnormalities secondary to lung disease
- •Sleep apnea syndrome
- •Suggested readings
- •19. Disorders of the respiratory pump
- •Neuromuscular disease affecting the muscles of respiration
- •Diaphragmatic disease
- •Disorders affecting the chest wall
- •Suggested readings
- •20. Lung cancer: Etiologic and pathologic aspects
- •Etiology and pathogenesis
- •Pathology
- •Suggested readings
- •21. Lung cancer: Clinical aspects
- •Clinical features
- •Diagnostic approach
- •Principles of therapy
- •Bronchial carcinoid tumors
- •Solitary pulmonary nodule
- •Suggested readings
- •22. Lung defense mechanisms
- •Physical or anatomic factors
- •Antimicrobial peptides
- •Phagocytic and inflammatory cells
- •Adaptive immune responses
- •Failure of respiratory defense mechanisms
- •Augmentation of respiratory defense mechanisms
- •Suggested readings
- •23. Pneumonia
- •Etiology and pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features and initial diagnosis
- •Therapeutic approach: General principles and antibiotic susceptibility
- •Initial management strategies based on clinical setting of pneumonia
- •Suggested readings
- •24. Bacterial and viral organisms causing pneumonia
- •Bacteria
- •Viruses
- •Intrathoracic complications of pneumonia
- •Respiratory infections associated with bioterrorism
- •Suggested readings
- •25. Tuberculosis and nontuberculous mycobacteria
- •Etiology and pathogenesis
- •Definitions
- •Pathology
- •Pathophysiology
- •Clinical manifestations
- •Diagnostic approach
- •Principles of therapy
- •Nontuberculous mycobacteria
- •Suggested readings
- •26. Miscellaneous infections caused by fungi, including Pneumocystis
- •Fungal infections
- •Pneumocystis infection
- •Suggested readings
- •27. Pulmonary complications in the immunocompromised host
- •Acquired immunodeficiency syndrome
- •Pulmonary complications in non–HIV immunocompromised patients
- •Suggested readings
- •28. Classification and pathophysiologic aspects of respiratory failure
- •Definition of respiratory failure
- •Classification of acute respiratory failure
- •Presentation of gas exchange failure
- •Pathogenesis of gas exchange abnormalities
- •Clinical and therapeutic aspects of hypercapnic/hypoxemic respiratory failure
- •Suggested readings
- •29. Acute respiratory distress syndrome
- •Physiology of fluid movement in alveolar interstitium
- •Etiology
- •Pathogenesis
- •Pathology
- •Pathophysiology
- •Clinical features
- •Diagnostic approach
- •Treatment
- •Suggested readings
- •30. Management of respiratory failure
- •Goals and principles underlying supportive therapy
- •Mechanical ventilation
- •Selected aspects of therapy for chronic respiratory failure
- •Suggested readings
- •Index
inhaler, maintenance (ongoing) therapy is provided with an anti-inflammatory agent to suppress the underlying airway inflammation, administered either alone or with an inhaled long-acting β2-agonist. Inhaled corticosteroids are used most frequently and appear to be the most effective anti-inflammatory agents, although leukotriene antagonists are alternatives.
Importantly, long-acting β2-agonist therapy should never be used in asthma without concomitant inhaled corticosteroid therapy because control of the disease may deteriorate and increased mortality may result. Options other than the regular use of a combined long-acting inhaled β2-agonist and inhaled corticosteroid are the addition of an antileukotriene agent to the regularly used inhaled corticosteroid, escalation of the dose of inhaled corticosteroids, or addition of the methylxanthine theophylline.
Long-acting inhaled anticholinergic medications and macrolide antibiotics (used primarily for antiinflammatory rather than antimicrobial effects) can be useful additions to the chronic treatment of severe asthma. Drugs that are targeted toward antagonizing specific biologic mediators, such as IgE, IL-4, IL-5 and others, are reserved for a very limited group of patients, typically those who have severe disease refractory to more traditional and cost-effective therapy.
When patients have a significant acute attack or an attack that occurs despite adequate therapy as described, intensive bronchodilator therapy plus a short course of systemic corticosteroids is typically effective. Particularly severe asthma exacerbations (i.e., status asthmaticus) often require high doses of systemic corticosteroids along with frequently administered bronchodilator therapy. In the extreme, patients with respiratory failure may require intubation and mechanical ventilation until their bronchospasm is reversed.
For patients in whom allergen exposure is an exacerbating factor for their asthma, allergen avoidance is a fundamental component of the management regimen. Environmental control measures to minimize allergen exposure include removing carpets, encasing mattresses and pillows in allergen-impermeable covers (to minimize dust mite exposure), and removing pets from the home (to minimize exposure to animal antigens). Immunotherapy with repeated injections of antigen extract is sometimes used to desensitize the patient to the offending allergen. Although immunotherapy is effective in allergic rhinitis, its efficacy in patients with asthma is controversial and its role uncertain.
Because of the availability of effective forms of therapy, patients with asthma and access to good medical care generally lead normal lives with relatively little or no alteration in their daily activities. However, not all patients with asthma are so fortunate. Even with treatment, some patients will experience refractory disease, persistent airflow obstruction, and rapid development of life-threatening attacks that pose a continuing challenge to physicians caring for these patients.
Suggested readings
Reviews
Chung K.F, Wenzel S.E, Brozek J.L, Bush A, Castro M, Sterk P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma European Respiratory Journal 2014;43: 343-373.
Cloutier M.M, Baptist A.P, Blake K.V, Brooks E.G, Bryant-Stephens T, DiMango E., et al.
2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group Journal of Allergy and Clinical Immunology 2020;146: 1217-1270.
King-Biggs M.B. Asthma Annals of Internal Medicine 2019;171: ITC49-ITC64.
McCracken J.L, Veeranki S.P, Ameredes B.T. & Calhoun W.J. Diagnosis and management of
asthma in adults. A review JAMA 2017;318: 279-290.
National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 3, NIH publication 08-4051 2007; National Institutes of Health Bethesda, MD.
Ramsahai J.M, Hansbro P.M. & Wark P.A.B. Mechanisms and management of asthma exacerbations American Journal of Respiratory and Critical Care Medicine 2019;199: 423-432.
Reddel H.K, Bacharier L.B, Bateman E.D, Brightling C.E, Brusselle G.G, Buhl R., et al.
Global Initiative for Asthma strategy 2021: Executive summary and rationale for key changes American Journal of Respiratory and Critical Care Medicine 2022;205: 17-35.
Schoettler N. & Strek M.E. Recent advances in severe asthma: From phenotypes to personalized medicine Chest 2020;157: 516-528.
Tarlo S.M. & Lemiere C. Occupational asthma New England Journal of Medicine 2014;370: 640-649.
Wenzel S.E. Severe adult asthmas: Integrating clinical features, biology, and therapeutics to improve outcomes American Journal of Respiratory and Critical Care Medicine 2021;203: 809-821.
White A.A. & Stevenson D.D. Aspirin-exacerbated respiratory disease New England Journal of Medicine 2018;379: 1060-1070.
Etiology and pathogenesis
Asher M.I, García-Marcos L, Pearce N.E. & Strachan D.P. Trends in worldwide asthma prevalence European Respiratory Journal 2020;56: 2002094.
Barnes P.J. Neurogenic inflammation in the airways Respiration Physiology 2001;125: 145154.
Busse W.W, Kraft M, Rabe K.F, Deniz Y, Rowe P.J, Ruddy M., et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
European Respiratory Journal 2021;58: 2003393.
Carr T.F, Zeki A.A. & Kraft M. Eosinophilic and noneosinophilic asthma American Journal of Respiratory and Critical Care Medicine 2018;197: 22-37.
El-Husseini Z.W, Gosens R, Dekker F. & Koppelman G.H. The genetics of asthma and the promise of genomics-guided drug target discovery Lancet Respiratory Medicine 2020;8: 1045-1056.
Fahy J.V. & Locksley R.M. Making asthma crystal clear New England Journal of Medicine 2019;381: 882-884.
Feldman A.S, He Y, Moore M.L, Hershenson M.B. & Hartert T.V. Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma American Journal of Respiratory and Critical Care Medicine 2015;191: 34-44.
Gauthier M, Ray A. & Wenzel S.E. Evolving concepts of asthma American Journal of Respiratory and Critical Care Medicine 2015;192: 660-668.
Gauvreau G.M, El-Gammal A.I. & O’Byrne P.M. Allergen-induced airway responses European Respiratory Journal 2015;46: 819-831.
Godson C. Balancing the effect of leukotrienes in asthma New England Journal of Medicine 2020;382: 1472-1475.
Heaney L.G, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica G.W., et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Eosinophilic and noneosinophilic asthma: An expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort Chest 2021;160: 814830.
Holgate S.T. Innate and adaptive immune responses in asthma Nature Medicine 2012;18: 673-683.
Holt P.G. & Sly P.D. Viral infections and atopy in asthma pathogenesis: New rationales for asthma prevention and treatment Nature Medicine 2012;18: 726-735.
Jartti T. & Gern J.E. Role of viral infections in the development and exacerbation of asthma in children Journal of Allergy and Clinical Immunology 2017;140: 895-906.
Kalchiem-Dekel O, Yao X. & Levine S.J. Meeting the challenge of identifying new treatments for type 2-low neutrophilic asthma Chest 2020;157: 26-33.
Lee A.S, Lee J.S, He Z. & Ryu J.H. Reflux-aspiration in chronic lung disease Annals of the American Thoracic Society 2020;17: 155-164.
Maciag M.C. & Phipatanakul W. Prevention of asthma: Targets for intervention Chest 2020;158: 913-922.
Mitchell P.D. & O’Byrne P.M. Epithelial-derived cytokines in asthma Chest 2017;151: 13381344.
Moldaver D.M, Larché M. & Rudulier C.D. An update on lymphocyte subtypes in asthma and airway disease Chest 2017;151: 1122-1130.
Pejler G. The emerging role of mast cell proteases in asthma European Respiratory Journal 2019;54: 1900685.
Saglani S. & Lloyd C.M. Novel concepts in airway inflammation and remodelling in asthma
European Respiratory Journal 2015;46: 1796-1804.
Wang M, Liu M, Wang C, Xiao Y, An T, Zou M., et al. Association between vitamin D status and asthma control: A meta-analysis of randomized trials Respiratory Medicine 2019;150: 85-94.
Clinical features and diagnostic approach
Anderson S.D. Indirect challenge tests: Airway hyperresponsiveness in asthma: Its measurement and clinical significance Chest 2010;138: 25S-30S.
Comberiati P, Katial R.K. & Covar R.A. Bronchoprovocation testing in asthma: An update
Immunology and Allergy Clinics of North America 2018;38: 545-571.
Corrao W.M, Braman S.S. & Irwin R.S. Chronic cough as the sole presenting manifestation of bronchial asthma New England Journal of Medicine 1979;300: 633-637.
Hallstrand T.S, Leuppi J.D, Joos G, Hall G.L, Carlsen K.H, Kaminsky D.A., et al. ERS technical standard on bronchial challenge testing: Pathophysiology and methodology of indirect airway challenge testing European Respiratory Journal 2018;52: 1801033.
Henneberger P.K, Redlich C.A, Callahan D.B, Harber P, Lemière C, Martin J., et al. An official American Thoracic Society statement: Work-exacerbated asthma American Journal of Respiratory and Critical Care Medicine 2011;184: 368-378.
Jackson D.J, Sykes A, Mallia P. & Johnston S.L. Asthma exacerbations: Origin, effect, and prevention Journal of Allergy and Clinical Immunology 2011;128: 1165-1174.
Louis R, Satia I, Ojanguren I, Schleich F, Bonini M, Tonia T., et al. European Respiratory Society guidelines for the diagnosis of asthma in adults European Respiratory Journal 2022;60: 2101585.
McFadden E.R,Jr, Kiser R. & DeGroot W.J. Acute bronchial asthma: Relations between
clinical and physiologic manifestations New England Journal of Medicine 1973;288: 221225.
Rupani H. & Kent B.D. Using fractional exhaled nitric oxide measurement in clinical asthma management Chest 2022;161: 906-917.
Wenzel S.E. Asthma phenotypes: The evolution from clinical to molecular approaches
Nature Medicine 2012;18: 716-725.
Treatment
Bleecker E.R, Menzies-Gow A.N, Price D.B, Bourdin A, Sweet S, Martin A.L., et al.
Systematic literature review of systemic corticosteroid use for asthma management
American Journal of Respiratory and Critical Care Medicine 2020;201: 276-293. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on
the management of asthma Thorax 2014;69: i1-i192.
Brusselle G.G. & Koppelman G.H. Biologic therapies for severe asthma New England Journal of Medicine 2022;386: 157-171.
Busse W.W, Bateman E.D, Caplan A.L, Kelly H.W, O’Byrne P.M, Rabe K.F., et al. Combined analysis of asthma safety trials of long-acting β2-agonists New England Journal of Medicine 2018;378: 2497-2505.
Cloutier M.M, Dixon A.E, Krishnan J.A, Lemanske R.F.Jr, Pace W. & Schatz M. Managing asthma in adolescents and adults: 2020 Asthma guideline update from the National Asthma Education and Prevention Program JAMA 2020;324: 2301-2317.
Durrani S.R, Viswanathan R.K. & Busse W.W. What effect does asthma treatment have on airway remodeling? Current perspectives Journal of Allergy and Clinical Immunology 2011;128: 439-448.
Gosens R. & Gross N. The mode of action of anticholinergics in asthma European Respiratory Journal 2018;52: 1701247.
Holguin F, Cardet J.C, Chung K.F, Diver S, Ferreira D.S, Fitzpatrick A., et al. Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline
European Respiratory Journal 2020;55: 1900588.
Israel E. & Reddel H.K. Severe and difficult-to-treat asthma in adults New England Journal of Medicine 2017;377: 965-976.
Kim L.H.Y, Saleh C, Whalen-Browne A, O’Byrne P.M. & Chu D.K. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and meta-analysis JAMA 2021;325: 2466-2479.
Laher A.E. & Buchanan S.K. Mechanically ventilating the severe asthmatic Journal of Intensive Care Medicine 2018;33: 491-501.
Mainardi A.S, Castro M. & Chupp G. Bronchial thermoplasty Clinics in Chest Medicine 2019;40: 193-207.
McGregor M.C, Krings J.G, Nair P. & Castro M. Role of biologics in asthma American Journal of Respiratory and Critical Care Medicine 2019;199: 433-445.
Mohan A, Ludwig A, Brehm C, Lugogo L.M, Sumino K. & Hanania N.A. Revisiting mild asthma: Current knowledge and future needs Chest 2022;161: 26-39.
O’Byrne P.M, Reddel H.K. & Beasley R. The management of mild asthma European Respiratory Journal 2021;57: 2003051.
Raissy H.H, Kelly H.W, Harkins M. & Szefler S.J. Inhaled corticosteroids in lung diseases American Journal of Respiratory and Critical Care Medicine 2013;187: 798-803.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Sobieraj D.M, Baker W.L, Nguyen E, Weeda E.R, Coleman C.I, White C.M., et al. Association of inhaled corticosteroids and long-acting muscarinic antagonists with asthma control in patients with uncontrolled, persistent asthma: A systematic review and meta-analysis
JAMA 2018;319: 1473-1484.
Soyka M.B, van de Veen W, Holzmann D, Akdis M. & Akdis C.A. Scientific foundations of allergen-specific immunotherapy for allergic disease Chest 2014;146: 1347-1357.
Suau S.J. & DeBlieux P.M. Management of acute exacerbation of asthma and chronic obstructive pulmonary disease in the emergency department Emergency Medicine Clinics of North America 2016;34: 15-37.
Tripple J.W, Ameredes B.T. & Calhoun W.J. Outpatient management of chronic asthma in 2020 JAMA 2020;323: 561-562.
Trivedi A, Pavord I.D. & Castro M. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma Lancet Respiratory Medicine 2016;4: 585-592.
van den Berge M, Hiemstra P.S. & Postma D.S. Genetics of glucocorticoids in asthma New England Journal of Medicine 2011;365: 2434-2435.
Wechsler M.E, Szefler S.J, Ortega V.E, Pongracic J.A, Chinchilli V, Lima J.J., et al. Step-up therapy in black children and adults with poorly controlled asthma New England Journal of Medicine 2019;381: 1227-1239.
Zaidan M.F, Ameredes B.T. & Calhoun W.J. Management of acute asthma in adults in 2020
JAMA 2020;323: 563-564.